November 5, 2024
Imugene (ASX:IMU) VAXINIA achieves major milestone in bile tract cancer treatment
A bile tract cancer patient in Imugene’s VAXINIA trial has achieved a remarkable two-year complete response, marking a significant milestone in the fight against advanced cancer.